Senologie - Zeitschrift für Mammadiagnostik und -therapie, Table of Contents Senologie - Zeitschrift für Mammadiagnostik und -therapie 2019; 16(02): 95-97DOI: 10.1055/a-0901-3615 Aktuell diskutiert © Georg Thieme Verlag KG Stuttgart · New York Stellungnahme der DGS zu Pertuzumab (Perjeta®) Recommend Article Abstract Buy Article Full Text References Literatur 1 Cronin KA, Lake AJ, Scott S. et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer 2018; 124: 2785-2800 2 Slamon DJ, Godolphin W, Jones LA. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712 3 Perez EA, Romond EH, Suman VJ. et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 2014; 32: 3744-3752 4 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.1, 2018 AWMF Registernummer: 032-045OL. Im Internet: http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/ Stand: 29.4.2019 5 Swain SM, Baselga J, Kim SB. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724-734 6 von Minckwitz G, Procter M, de Azambuja E. et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med 2017; 377: 122-131 7 Wallwiener CW, Hartkopf AD, Grabe E. et al. Adjuvant chemotherapy in elderly patients with primary breast cancer: are women >/=65 undertreated?. J Cancer Res Clin Oncol 2016; 142: 1847-1853 8 Mislang AR, Biganzoli L. Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?. Cancers (Basel) 2015; 7: 1191-1214 9 Zwiener BM, Hommel G. Survival analysis – part 15 of a series on evaluation of scientific publications. Dtsch Arztebl Int 2011; 108: 163-169 10 Lassere MN. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res 2008; 17: 303-340
